Corvus Pharmaceuticals Suspends At-The-Market Equity Program

Corvus Pharmaceuticals ( (CRVS) ) just unveiled an update.

On January 20, 2026, Corvus Pharmaceuticals, Inc. suspended, in connection with a proposed registered underwritten public offering, its previously established at-the-market equity program with Jefferies LLC under which up to $100 million of common stock could be sold pursuant to a prospectus supplement filed on August 6, 2024 and an effective shelf registration statement. No shares had been sold under this ATM facility prior to the suspension, leaving the entire $100 million capacity unused, and while the underlying sales agreement with Jefferies remains in force, the company will not conduct any sales under it unless and until it files a new prospectus supplement or registration statement with the SEC, signaling a shift in near-term capital-raising strategy that may affect the timing and structure of future equity issuance for investors and other stakeholders.

The most recent analyst rating on (CRVS) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.

Spark’s Take on CRVS Stock

According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.

The score is held back primarily by weak financial performance (pre-revenue with ongoing losses and material cash burn). The latest earnings call provides support via improved quarterly loss trends, a cash runway into Q4 2026, and meaningful clinical trial progress, but near-term technical momentum is soft and valuation is constrained by negative earnings.

To see Spark’s full report on CRVS stock, click here.

More about Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company that raises capital through public equity offerings, including at-the-market (ATM) programs, to fund its operations and development activities within the pharmaceutical and life sciences sector.

Average Trading Volume: 1,344,680

Technical Sentiment Signal: Buy

Current Market Cap: $601.2M

For an in-depth examination of CRVS stock, go to TipRanks’ Overview page.